Canada
· Delayed Price · Currency is CAD InnoCan Pharma Statistics
Total Valuation
InnoCan Pharma has a market cap or net worth of CAD 60.26 million. The enterprise value is 55.84 million.
| Market Cap | 60.26M |
| Enterprise Value | 55.84M |
Important Dates
The next estimated earnings date is Thursday, November 28, 2024.
| Earnings Date | Nov 28, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
InnoCan Pharma has 286.94 million shares outstanding. The number of shares has increased by 7.44% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 286.94M |
| Shares Change (YoY) | +7.44% |
| Shares Change (QoQ) | +4.02% |
| Owned by Insiders (%) | 5.42% |
| Owned by Institutions (%) | 0.18% |
| Float | 221.67M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.48 |
| PB Ratio | 8.50 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -15.88 |
| EV / Sales | 1.43 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -17.18 |
Financial Position
The company has a current ratio of 3.57, with a Debt / Equity ratio of 0.00.
| Current Ratio | 3.57 |
| Quick Ratio | 1.91 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.00 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -17.66% and return on invested capital (ROIC) is -13.33%.
| Return on Equity (ROE) | -17.66% |
| Return on Assets (ROA) | -9.28% |
| Return on Capital (ROIC) | -13.33% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 3.51 |
| Inventory Turnover | 1.12 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -33.33% in the last 52 weeks. The beta is 2.99, so InnoCan Pharma's price volatility has been higher than the market average.
| Beta (5Y) | 2.99 |
| 52-Week Price Change | -33.33% |
| 50-Day Moving Average | 0.22 |
| 200-Day Moving Average | 0.26 |
| Relative Strength Index (RSI) | 45.33 |
| Average Volume (20 Days) | 55,679 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, InnoCan Pharma had revenue of CAD 39.08 million and -3.52 million in losses. Loss per share was -0.01.
| Revenue | 39.08M |
| Gross Profit | 35.22M |
| Operating Income | -1.65M |
| Pretax Income | 451,217 |
| Net Income | -3.52M |
| EBITDA | -1.60M |
| EBIT | -1.65M |
| Loss Per Share | -0.01 |
Balance Sheet
The company has 6.83 million in cash and 1,351 in debt, giving a net cash position of 6.83 million or 0.02 per share.
| Cash & Cash Equivalents | 6.83M |
| Total Debt | 1,351 |
| Net Cash | 6.83M |
| Net Cash Per Share | 0.02 |
| Equity (Book Value) | 9.38M |
| Book Value Per Share | 0.02 |
| Working Capital | 9.22M |
Cash Flow
In the last 12 months, operating cash flow was -3.22 million and capital expenditures -27,019, giving a free cash flow of -3.25 million.
| Operating Cash Flow | -3.22M |
| Capital Expenditures | -27,019 |
| Free Cash Flow | -3.25M |
| FCF Per Share | -0.01 |
Margins
Gross margin is 90.11%, with operating and profit margins of -4.22% and -9.00%.
| Gross Margin | 90.11% |
| Operating Margin | -4.22% |
| Pretax Margin | 1.15% |
| Profit Margin | -9.00% |
| EBITDA Margin | -4.10% |
| EBIT Margin | -4.22% |
| FCF Margin | -8.32% |
Dividends & Yields
InnoCan Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -7.44% |
| Shareholder Yield | -7.44% |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |